Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2020

View Archived Issues

Innovent initiates phase I/II studies of IBI-318

Blood cells. Lots of them

FDA accepts IND application for phase Ia study of PRA-023

First participant dosed in phase I study of TBAJ-587

Sichuan Haisco Pharmaceutical patents CRBN-comprising PROTACs

Galapagos discloses new SIK inhibitors

Shanghai Zhimeng Biopharma presents new KCNQ2 activators

KEAP1/NRF2 interaction inhibitors presented by Ube Industries

Positive final data presented from COMBAT/KEYNOTE-202 triple combination study in PDAC

GenScript discloses new CD47 and PD-L1-targeting proteins

Evaluation of the modafinil analogue (S,S)-CE-158 in neurochemical and behavioral studies in rats

Cerecor initiates dosing in phase Ib study of CERC-007 in relapsed/refractory multiple myeloma

NP + GPC DNA vaccine candidate protects cynomolgus macaques from Crimean-Congo hemorrhagic fever

Topline data from phase II study of vocacapsaicin in total knee arthroplasty surgery

Researchers develop a mitometin-testing murine model of ALS

First subjects dosed in phase I study of PN-235

Abpro initiates phase II/III registrational studies of ABP-300 as treatment of COVID-19

FDA places partial clinical hold on odronextamab lymphoma trials

Phase I data presented for cannabidivarin for treating epilepsy in patients with Rett syndrome

Through mTOR, ketamine affects protein translation hub

FDA approves Margenza for pretreated metastatic HER2-positive breast cancer

New phase III trial evaluates siltuximab for COVID-19 or viral-associated ARDS

Molecular Partners advances pipeline

Heat Biologics completes ZVX-60 gp96-based COVID-19 vaccine cell line

Interim phase II data for darolutamide demonstrate efficacy in advanced AR-positive TNBC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...